MGTA Magenta Therapeutics Inc.

13.14
+0.13  (+1%)
Previous Close 13.01
Open 12.9
Price To Book 2.84
Market Cap 509,402,217
Shares 38,767,292
Volume 106,616
Short Ratio
Av. Daily Volume 69,237
Stock charts supplied by TradingView

NewsSee all news

  1. Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    –Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH–  –Reported first-ever successful gene

  2. Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR

    -- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- Magenta exercises option with Heidelberg Pharma

  3. Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting

    -- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented

  4. Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Will evaluate development as less toxic conditioning becomes available.
MGTA-456
Sickle cell disease
Phase 2 data noted all patients met primary endpoint.
MGTA-456
Inherited Metabolic Disorders (IMD)
Phase 2 data due at ASH December 9, 2019, 4pm EST.
MGTA-456
Acute Lymphoblastic Leukemia
Phase 1 initial data due at ASH December 7, 2019, 5:30pm.
MGTA-145
Healthy volunteers

Latest News

  1. Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    –Early clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of cells in 11 of 12 healthy volunteers; updated data to be presented at ASH–  –Reported first-ever successful gene

  2. Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR

    -- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- Magenta exercises option with Heidelberg Pharma

  3. Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting

    -- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented

  4. Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders

    Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug